miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy
暂无分享,去创建一个
Woonyoung Choi | Liana Adam | G. Calin | M. Nicoloso | C. Dinney | D. McConkey | M. Bar‐eli | A. Siefker-Radtke | W. Choi | L. Adam | Hua Wang | Menashe Bar-Eli | Milena Nicoloso | Colin Dinney | David McConkey | Meng Zhong | Wei Qi | Ameeta Arora | George Calin | Hua Wang | Arlene Siefker-Radtke | W. Qi | Ameeta Arora | Meng Zhong
[1] R. Dreicer. Advanced bladder cancer: So many drugs, so little progress , 2008, Cancer.
[2] M. Korpal,et al. The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional Repressors ZEB1 and ZEB2* , 2008, Journal of Biological Chemistry.
[3] Wenjun Guo,et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.
[4] G. Goodall,et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.
[5] Sun-Mi Park,et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.
[6] A. Atala,et al. Expression-targeted gene therapy for the treatment of transitional cell carcinoma , 2008, Cancer Gene Therapy.
[7] Xifeng Wu,et al. Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells , 2008, Clinical Cancer Research.
[8] C. L. Murphy,et al. Hypoxia Promotes the Differentiated Human Articular Chondrocyte Phenotype through SOX9-dependent and -independent Pathways* , 2008, Journal of Biological Chemistry.
[9] A. Yoshimura,et al. E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib. , 2008, Oncology reports.
[10] 宮永 晃彦. E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib , 2008 .
[11] F. Sicheri. Faculty Opinions recommendation of Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. , 2007 .
[12] O. Segatto,et al. The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity , 2007, Oncogene.
[13] R. Weinberg,et al. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer , 2007, Nature.
[14] R. Herbst,et al. Expression of epidermal growth factor (EGF)/transforming growth factor-α by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice , 2007, Molecular Cancer Therapeutics.
[15] C. Dinney,et al. Emerging drugs for targeted therapy of bladder cancer , 2007, Expert opinion on emerging drugs.
[16] S. Spivack,et al. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. , 2007, Cancer research.
[17] Manuel Hidalgo,et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] G. V. Vande Woude,et al. Mig-6, Signal Transduction, Stress Response and Cancer , 2007, Cell cycle.
[19] C. Dinney,et al. Molecular correlates of gefitinib responsiveness in human bladder cancer cells , 2007, Molecular Cancer Therapeutics.
[20] C. Croce,et al. MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.
[21] K. Aldape,et al. Mutations Within the Kinase Domain and Truncations of the Epidermal Growth Factor Receptor Are Rare Events in Bladder Cancer: Implications for Therapy , 2006, Clinical Cancer Research.
[22] F. Slack,et al. Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.
[23] J. Minna,et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. , 2006, Cancer research.
[24] R. Shiekhattar,et al. MicroRNA biogenesis: isolation and characterization of the microprocessor complex. , 2006, Methods in molecular biology.
[25] P. Carroll,et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] J. Pettitt. The cadherin superfamily. , 2005, WormBook : the online review of C. elegans biology.
[27] G. Cavet,et al. Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients , 2005, Clinical Cancer Research.
[28] R. Shiekhattar,et al. Human RISC Couples MicroRNA Biogenesis and Posttranscriptional Gene Silencing , 2005, Cell.
[29] Liana Adam,et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. , 2005, Cancer research.
[30] E. Brown,et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. , 2005, Cancer research.
[31] M. Mann,et al. Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.
[32] D. Haber,et al. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. , 2005, Cold Spring Harbor symposia on quantitative biology.
[33] R. Millikan,et al. Focus on bladder cancer. , 2004, Cancer cell.
[34] K. Carraway,et al. Negative regulation of ErbB family receptor tyrosine kinases , 2004, British Journal of Cancer.
[35] Steve Mirsky,et al. What's Wrong with This Picture? , 2003 .
[36] G. Sala,et al. Feedback inhibition by RALT controls signal output by the ErbB network , 2003, Oncogene.
[37] H Steven Wiley,et al. Trafficking of the ErbB receptors and its influence on signaling. , 2003, Experimental cell research.
[38] G. Sala,et al. Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control , 2002, Oncogene.
[39] L. E. Johannessen,et al. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies , 2002, The Journal of cell biology.
[40] J. Gutkind,et al. Signaling from E-cadherins to the MAPK Pathway by the Recruitment and Activation of Epidermal Growth Factor Receptors upon Cell-Cell Contact Formation* , 2000, The Journal of Biological Chemistry.
[41] M. Crescenzi,et al. Inhibition of ErbB-2 Mitogenic and Transforming Activity by RALT, a Mitogen-Induced Signal Transducer Which Binds to the ErbB-2 Kinase Domain , 2000, Molecular and Cellular Biology.
[42] J. Bonventre,et al. Gene 33/Mig-6, a Transcriptionally Inducible Adapter Protein That Binds GTP-Cdc42 and Activates SAPK/JNK* , 2000, The Journal of Biological Chemistry.
[43] A. Brunet,et al. Nuclear translocation of p42/p44 mitogen‐activated protein kinase is required for growth factor‐induced gene expression and cell cycle entry , 1999, The EMBO journal.
[44] A. Lenferink,et al. Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers , 1998, The EMBO journal.
[45] C. Bucana,et al. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. , 1995, The Journal of urology.